Immunological effects of dimethyl fumarate treatment in blood and CSF of patients with primary progressive MS

Dimethyl Fumarate Treatment in Patients With Primary Progressive Multiple Sclerosis

(2021) Helene Højsgaard Chow et al.   Neurology-Neuroimmunology & Neuroinflammation

The window of opportunity for treatment of progressive multiple sclerosis

(2020) Per Soelberg Sorensen et al.   CURRENT OPINION IN NEUROLOGY

Pathogenic Mechanisms Associated With Different Clinical Courses of Multiple Sclerosis

(2019) Hans Lassmann   Frontiers in Immunology

Effect of dimethyl fumarate on lymphocytes in RRMS

(2019) Devangi Mehta et al.   NEUROLOGY

Dimethyl fumarate impairs differentiated B cells and fosters central nervous system integrity in treatment of multiple sclerosis

(2019) Jan Traub et al.   BRAIN PATHOLOGY

Optimal response to dimethyl fumarate is mediated by a reduction of Th1‐like Th17 cells after 3 months of treatment

(2019) María José Mansilla et al.   CNS Neuroscience & Therapeutics

Therapeutic efficacy of dimethyl fumarate in relapsing-remitting multiple sclerosis associates with ROS pathway in monocytes

(2019) Karl E. Carlström et al.   Nature Communications

Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis

(2019) Colm Elliott et al.   BRAIN

Dimethyl fumarate therapy reduces memory T cells and the CNS migration potential in patients with multiple sclerosis

(2019) Rikke Holm Hansen et al.   Multiple Sclerosis and Related Disorders

Inflammatory intrathecal profiles and cortical damage in multiple sclerosis

(2018) Roberta Magliozzi et al.   ANNALS OF NEUROLOGY

Dimethyl fumarate targets GAPDH and aerobic glycolysis to modulate immunity

(2018) Michael D. Kornberg et al.   SCIENCE

Emerging Understanding of the Mechanism of Action for Dimethyl Fumarate in the Treatment of Multiple Sclerosis

(2018) Elizabeth A. Mills et al.   Frontiers in Neurology

Dimethyl fumarate therapy suppresses B cell responses and follicular helper T cells in relapsing-remitting multiple sclerosis

(2018) Rikke Holm Hansen et al.   Multiple Sclerosis Journal

B-cell composition in the blood and cerebrospinal fluid of multiple sclerosis patients treated with dimethyl fumarate

(2018) Rune A. Høglund et al.   Multiple Sclerosis and Related Disorders

Dimethyl Fumarate Selectively Reduces Memory T Cells and Shifts the Balance between Th1/Th17 and Th2 in Multiple Sclerosis Patients

(2017) Qi Wu et al.   JOURNAL OF IMMUNOLOGY

Treatment response to dimethyl fumarate is characterized by disproportionate CD8+ T cell reduction in MS

(2017) Vinzenz Fleischer et al.   Multiple Sclerosis Journal

Treatment response to dimethyl fumarate is characterized by disproportionate CD8+ T cell reduction in MS

(2017) Vinzenz Fleischer et al.   Multiple Sclerosis Journal

Dimethyl Fumarate Treatment Mediates an Anti-Inflammatory Shift in B Cell Subsets of Patients with Multiple Sclerosis

(2016) Rui Li et al.   JOURNAL OF IMMUNOLOGY

Circulating innate lymphoid cells are unchanged in response to DAC HYP therapy

(2016) Geoffrey O. Gillard et al.   JOURNAL OF NEUROIMMUNOLOGY

Dimethyl fumarate blocks pro-inflammatory cytokine production via inhibition of TLR induced M1 and K63 ubiquitin chain formation

(2016) Victoria A. McGuire et al.   Scientific Reports

DMF, but not other fumarates, inhibits NF-κB activity in vitro in an Nrf2-independent manner

(2015) Geoffrey O. Gillard et al.   JOURNAL OF NEUROIMMUNOLOGY

Hydroxycarboxylic acid receptor 2 mediates dimethyl fumarate’s protective effect in EAE

(2014) Hui Chen et al.   JOURNAL OF CLINICAL INVESTIGATION

Dimethyl Fumarate Inhibits Dendritic Cell Maturation via Nuclear Factor κB (NF-κB) and Extracellular Signal-regulated Kinase 1 and 2 (ERK1/2) and Mitogen Stress-activated Kinase 1 (MSK1) Signaling

(2012) Haiyan Peng et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis

(2012) Robert J. Fox et al.   NEW ENGLAND JOURNAL OF MEDICINE

Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis

(2012) Ralf Gold et al.   NEW ENGLAND JOURNAL OF MEDICINE

Homeostasis of Naive and Memory T Cells

(2008) Charles D. Surh et al.   IMMUNITY

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

(2008) Ludwig Kappos et al.   LANCET